DYN•benzinga•
Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday?
Summary
Dyne Therapeutics' DYNE-101 shows promising Phase 1/2 results for myotonic dystrophy type 1, with plans for Accelerated Approval by 2026.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 10, 2025 by benzinga